EU and US could reach trade deal this weekend - Reuters
On Tuesday, H.C. Wainwright analyst Raghuram Selvaraju adjusted the price target for BioNTech (NASDAQ:BNTX) shares, bringing it down to $145 from the previous $150, while maintaining a Buy rating on the company. The stock, currently trading at $91.06, has seen analyst targets ranging from $110 to $171. According to InvestingPro data, three analysts have recently revised their earnings expectations upward for the upcoming period. This change follows the presentation of Phase 2 data at the European Lung Cancer Congress (ELCC) 2025.
BioNTech unveiled results for its BNT327 combined with chemotherapy in first-line extensive-stage small cell lung cancer (ES-SCLC) and second-line SCLC. The first-line dataset showed an impressive 87.5% objective response rate (ORR), with a median progression-free survival (mPFS) of 6.9 months and median overall survival (mOS) of 16.8 months among 48 evaluated patients. These results appear to outperform the outcomes from the IMpower133 trial of Tecentriq plus chemotherapy. The company maintains strong financial health with a current ratio of 7.45 and minimal debt, as revealed by InvestingPro analysis.
Selvaraju believes that these findings reduce the risk associated with BioNTech’s ongoing Phase 3 trial, BNT327-03, which compares BNT327 plus chemotherapy against Tecentriq plus chemotherapy for first-line ES-SCLC patients. The analyst also noted the absence of Phase 3 trials for ivonescimab in this indication, despite its Phase 1b results being published.
In the second-line SCLC setting, BNT327 plus chemotherapy showed a 56.9% ORR, with a 5.5-month mPFS and a 14.3-month mOS, demonstrating similar efficacy in both immunotherapy-naive and pretreated patients. This compares favorably to Amgen (NASDAQ:AMGN)’s IMDELLTRA, which received accelerated approval based on a 40% ORR in its own Phase 2 trial.
Following the update to the projected revenues for 2025, H.C. Wainwright reaffirmed their Buy rating but lowered the 12-month price target to $145 per share, down from the previous target of $150. The adjustment reflects the latest clinical data and market expectations for BioNTech’s ongoing research and development in treating SCLC. InvestingPro analysis suggests the stock is currently undervalued, with additional metrics and insights available in the comprehensive Pro Research Report, which provides deep-dive analysis of BioNTech’s financial health, valuation, and growth prospects.
In other recent news, BioNTech reported its fourth-quarter earnings, with revenues of €1.19 billion, surpassing consensus estimates by approximately 6%. Despite this, the company’s fiscal year 2025 revenue forecast of €1.7 billion to €2.2 billion fell short of the expected €2.5 billion. BMO Capital Markets responded by raising BioNTech’s price target to $143, maintaining an Outperform rating due to BioNTech’s strategic shift towards oncology. Meanwhile, Truist Securities revised its price target for BioNTech to $151 from $172, maintaining a Buy rating, acknowledging the company’s potential despite a cautious revenue outlook. Jefferies also maintained a Buy rating with a $149 target, noting that BioNTech’s EPS of €1.08 exceeded expectations.
Additionally, CureVac received a favorable ruling from the European Patent Office in its legal proceedings against BioNTech, upholding a crucial patent with amendments. This development is significant as it could lead to further legal proceedings to determine potential patent infringement and damages. Berenberg reaffirmed a Buy rating for BioNTech, with a $130 price target, following promising Phase 2 trial data for its investigational drug BNT327 targeting small cell lung cancer. BioNTech’s recent clinical trial setback with its personalized cancer vaccine candidate, BNT122, has also drawn attention, as it failed in a study involving patients with advanced metastatic melanoma. These developments highlight the ongoing strategic and financial dynamics within BioNTech and CureVac.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.